Meeting
2017 ASCO Annual Meeting
A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
Authors
Jose A. Lopez-Martin
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain
Jose A. Lopez-Martin , Alfonso Berrocal , María González-Cao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02583516
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9599)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9599
Abstract #
TPS9599
Poster Bd #
203a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long
Poster
2015 ASCO Annual Meeting
Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).
First Author: Melissa K. Yee
Poster
2020 ASCO Virtual Scientific Program
A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
First Author: Paola Queirolo
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan